Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sumitomo Dainippon Pharma
Biotech
Sumitomo-Otsuka schizophrenia drug flunks pair of phase 3 trials
The trials missed their primary endpoints, leaving the partners looking to a “high placebo response” for evidence that the asset has a future.
Nick Paul Taylor
Jul 31, 2023 7:50am
Sumitomo Pharma tidies up 7 units into one combined US entity
Apr 3, 2023 12:16pm
Sumitomo inks Myovant $2.9B buyout, adding IVF asset to pipeline
Oct 24, 2022 7:00am
Jazz pays $50M for rights to early-phase narcolepsy prospect
May 5, 2022 8:30am
Roivant CEO Ramaswamy hands reins to CFO Gline
Jan 25, 2021 10:55am
Ahead of possible approval, Metavant backs off imeglimin
Nov 20, 2020 8:30am
